11:41 AM
 | 
Sep 01, 2017
 |  BioCentury  |  Finance

Armo's China network

Why Armo brought Chinese investors on board for its $67M series C-1 round

Chinese investors in Armo BioSciences Inc.'s $67 million series C-1 round could help the Redwood City, Calif., company establish local partnerships and bring its lead cancer therapy to the China market.

Qiming Venture Partners led the untranched round, and was joined by fellow China-based new investors Decheng Capital, Quan Capital and Sequoia Capital. RTW Investment, also a new investor, and existing investors Kleiner Perkins Caufield & Byers, OrbiMed Advisors, DAG Ventures, NanoDimension, HBM Healthcare Investments, GV, Celgene Corp. (NASDAQ:CELG) and funds advised by...

Read the full 413 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >